Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page Small font size Default font size Increase font size Users Online: 1597
ORIGINAL ARTICLE
Year : 2011  |  Volume : 17  |  Issue : 2  |  Page : 55-59

Efficacy and safety of doxazosin (Cardura TM ) in the management of Benign Prostatic Hyperplasia


1 Urology Unit, Lagoon Hospital Apapa, Lagos, Nigeria
2 Pfizer Specialties Ltd
3 Department of Surgery, College of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria

Correspondence Address:
E A Jeje
Department of Surgery, College of Medicine University of Lagos
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective: To assess the efficacy and safety of the selective a!-blocker doxazosin in black men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia. Patients and Methods : An open-label study involving consecutive patients with benign prostatic hyperplasia. They were asked to complete the International Prostate Symptom Score (IPSS), with its eighth question (bother score) and perform basic uroflowmetry. The study involved the use of doxazosin for the treatment of symptomatic benign prostatic hyperplasia in three phases. Phase 1 of washout period/enrolment, a two weekly interval titration phase and a maintenance phase for four weeks. The symptom score (IPSS), bother score and uroflowmetry were used to evaluate the severity of the condition and the efficacy of the drug. Results: Twenty-four patients were enrolled into the study, only 18(75%) completed the eight-week study. The ages of the patients ranged between 46 years and 82 years with a mean of 66 years. (SD, 10.0) Fourteen patients were stabilized on 4mg doxazosin while the remaining 4 patients had 2mg. There was significant improvement of the symptoms, with a remarkable sharp decline after two weeks of medication in IPS S by 8 points from baseline. The improvement was sustained over the following six weeks period. The bother score (quality of life index) was similarly observed to decline from a mean of 4.7 at baseline to 1.3 at the end of the study. The clinical trial showed a significant increase in the urine flow rate with an improvement of 4mls/second from baseline and a 24.1 % increase in voided volume. There was no adverse event recorded in all the patients to warrant discontinuation of the study. Conclusion: Doxazosin is an effective and well tolerated drug in the treatment of symptomatic BPH inNigerians.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1975    
    Printed85    
    Emailed0    
    PDF Downloaded4543    
    Comments [Add]    

Recommend this journal